TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Safety of MRI-guided radioembolization procedure
Endpoint domain: Adverse events/effects
Primary endpoint: The number and incidence rate of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: The number and incidence rate of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Systolic and Diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in metabonomics pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in cytokine pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of high-sensitivity Troponin assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite of all-cause mortality or nursing home admission
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Work and Social Adjustment Scale (WSAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Oxygenation at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenation at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatability of Bar
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Imaging parameters of obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Question 3 of the Patient Sexual Encounter Profile (SEP) Diary at Week 12 in Percentage of Yes Responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhaler technique improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes from the HAM-A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Delay-Discounting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reinforcement Learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in knee functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient Transplant Medication and Care Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Satisfaction with Educational Method
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of completing per protocol treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salivary IgA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of patients requiring hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to hospitalization measured in days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Specific gene expressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type and concentration of inflammatory cells present
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Selective biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum inter-incisal opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced Cravings for Opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse to Illicit Opioid Use
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of liver metastasectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of Bisphenol A and paraben in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sensitization to GRPs-containing foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of individual preformed HLA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Local Reactions Within 7 Days After Administration of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Administration of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AE) Within 1 Month After Administration of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAE) Within 1 Month After Administration of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of sick leaves
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Daytime Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Nighttime Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Palpation Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain measured by FACES pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain measured by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative nausea measured by BARF scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of DMF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predictive power of pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: predictive power of irAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Mind Body Connection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changed Incidence of Medical School Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in non-inflammatory acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in inflammatory acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in total acne lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in acne severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Apparent terminal elimination half-life (t½λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target vessel patency rate evaluated by postoperative ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Serve accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of SGLT2i
Endpoint domain: Adverse events/effects
Primary endpoint: Pap test intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Circulating immune cell abundance and function pre-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circulating immune cell mobilization and function post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sleep State Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Determinants of Behavior Questionnaire (DIBQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunologic Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Steroid-induced Ocular Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Laboratory-confirmed SARS-CoV-2 Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical Rating Scale (NRS) for pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cognitive flexibility by local switch cost RT (Switch Task)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Perceived feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protocol deviations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: proportion of restrictive lung physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in urge predominate urinary incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of Neonatal Morbidity and Perinatal Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of moderate or higher neonatal respiratory support within 72 hours after birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of neonatal intensive care unit (NICU) > 1 day (24 hours) stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Perceived independence in daily life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Upper extremity functionality in daily life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAD Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Vertigo Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dix Hallpike Maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture assessment scale for stroke (PASS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first rescue analgesic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction assessed using the Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients with complete healing by Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who maintain complete healing through Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of point-of-care ultrasound on identifying hydronephrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with microscopic myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of patients with any grade 3-5 Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean scores of sexual function using IIEF for men
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Mean scores of sexual function using FSFI for women
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Rate of Biological Aging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcomes Measurement Information system-29 Physical Function Sub-domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of muscle deoxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle reoxygenation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cross-reactivity of SARS-CoV-2-specific T-cells with insulin producing cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of participants categorized as frail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of enrolled participants per month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion eligible after screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neuroimaging information
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Low frequency of systolic blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient and Caregiver Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Genetic modifiers in haemoglobinopathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of MRD-negative complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Creatinin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemorrhagic syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalisation in intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PROMIS-29 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Fear of Cancer Recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IKDC Subjective Knee Score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Objective Response Rate (CORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of Gilteritinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cervical Joint Position Sense Error (JPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perception of Needle Penetrating the Skin
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Hearing Threshold (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal changes in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal changes in quality of life (physical, psychological and social function in patients with cancer)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Longitudinal changes in muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gluten immunogenic peptides in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer-specific survival (CSS) rate at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Cancer-specific survival (CSS) rate at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Randomization proportion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of protocol completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of DLTs, AESIs, Grade 3 or higher TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in clinical laboratory tests results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in vital signs results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Itch Severity Scale (ISS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate (ORR) per RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of delirium-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of coma free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to First AVG Thrombosis Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Thirst Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants able to consent for off-label medication use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in peripheral oxytocin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall response rate (ORR) based on investigator assessment against RECIST 1.1 criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative intra- and postoperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fasting capillary blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Arterial Blood Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in skin surface temperature at acupuncture site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edema severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PCI related myocardial injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of colistin induced nephrotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability as measured by Safteesi survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety profile and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: GI Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: width of palate after expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of digital impressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Cephen reagents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in NAFLD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in histological fibrosis Ishak score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer Assessment for the upper extremity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of Maribavir on CMV Viremia Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Viral Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Drug Resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse reactions 0~7 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse reactions 0~30 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Positive (4-fold change) rate of serum Pneumococcal surface protein antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average time to full daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with adverse events related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone resorption distal to second molar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive Gestational Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct management plan at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Resistive Index (RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in regional ventilation distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite Endpoint Alkaline Phosphatase (ALP) and Total Bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symphyseal diastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Motor-Free Visual Perception Test-3rd Edition (MVPT-3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes